Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Plus mFOLFIRINOX in Locally Advanced Pancreatic Cancer
NCT06153368Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2023
- Primary completion
- Nov 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in pancreatic cancer (PC), sponsored by Jiangsu Provincial People's Hospital. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06153368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06153368.